Voro Therapeutics has entered into a research collaboration with Daiichi Sankyo to develop next-generation antibody-drug conjugates (ADCs) using its proprietary PrimeBody platform. The partnership, conducted through Daiichi Sankyo’s Research Institute in San Diego, aims to advance a new class of tumor-activated biologics designed to improve the safety and effectiveness of cancer therapies.
The collaboration will focus on leveraging Voro’s PrimeBody technology to generate “masked” ADC candidates. These therapies are engineered to remain inactive while circulating in the body and in healthy tissues, becoming activated only within the tumor microenvironment. This tumor-selective activation is achieved through specialized masking domains and protease-cleavable linkers, which are designed to unlock the therapeutic payload specifically at the disease site.
ADCs have emerged as a powerful approach in oncology by combining the targeting ability of antibodies with the potency of cytotoxic drugs. However, one of the longstanding challenges with ADCs has been balancing efficacy with safety, as off-target effects can lead to toxicity in healthy tissues. By introducing a mechanism that controls when and where the drug becomes active, Voro’s platform seeks to expand the therapeutic index—maximizing anti-tumor activity while minimizing side effects.
Under the terms of the agreement, Voro Therapeutics will apply its masking and linker technologies to design and characterize ADC candidates directed at a selected oncology target. The collaboration builds on Voro’s previous work in tumor-activated biologics, including its lead CD47 blocker program, which has demonstrated improved therapeutic index in preclinical studies.
Ugur Eskiocak, Co-Founder and CEO of Voro Therapeutics, emphasized that unlocking the full potential of highly potent drug payloads requires precise control over activation. He noted that the PrimeBody platform could enable targeting of antigens that were previously considered unsuitable due to their expression in healthy tissues, thereby expanding the range of treatable cancers.
Daiichi Sankyo, widely recognized for its expertise in ADC development, brings significant experience in advancing innovative oncology therapies. The collaboration reflects the company’s continued commitment to exploring cutting-edge technologies that can enhance the performance of targeted cancer treatments.
While financial details of the agreement were not disclosed, the partnership underscores a growing trend in the biopharmaceutical industry toward smarter, more selective therapies. By combining Voro’s tumor-activated biologics platform with Daiichi Sankyo’s ADC development capabilities, the companies aim to push the boundaries of precision oncology.
If successful, the collaboration could pave the way for safer and more effective ADC therapies, offering new hope for patients with difficult-to-treat cancers while addressing key limitations of existing treatment approaches.